Atypical inflammatory demyelinating syndromes of the CNS. (Q31118850)

29 June 2017

1 reference

title

Atypical inflammatory demyelinating syndromes of the CNS. (English)

1 reference

29 June 2017

4

Jacqueline Palace

1 reference

29 June 2017

6

Brian G Weinshenker

1 reference

29 June 2017

Todd A Hardy

1

1 reference

29 June 2017

Stephen W Reddel

series ordinal

2

1 reference

29 June 2017

Michael H Barnett

series ordinal

3

1 reference

29 June 2017

Claudia F Lucchinetti

series ordinal

5

1 reference

29 June 2017

1 August 2016

1 reference

29 June 2017

1 reference

29 June 2017

15

1 reference

29 June 2017

967-981

1 reference

29 June 2017

9

1 reference

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

29 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The pathological spectrum of CNS inflammatory demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Marburg's Variant of Multiple Sclerosis Correlates with a Less Compact Structure of Myelin Basic Protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Revised diagnostic criteria for neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The spectrum of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Demographic and clinical features of neuromyelitis optica: A review.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica pathogenesis and aquaporin 4

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Aquaporin 4 and neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica: a positive appraisal of seronegative cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

MRI characteristics of neuromyelitis optica spectrum disorder: an international update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Conventional and advanced imaging in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

A benign form of neuromyelitis optica: does it exist?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica and astrocytic damage in its pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Pathology of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Persistence of immunopathological and radiological traits in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Beneficial plasma exchange response in central nervous system inflammatory demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Consensus definitions proposed for pediatric multiple sclerosis and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

A long-term follow-up study using IPMSSG criteria in children with CNS demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The magnetic resonance imaging appearance of monophasic acute disseminated encephalomyelitis: an update post application of the 2007 consensus criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The spectrum of MOG autoantibody-associated demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute disseminated encephalomyelitis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Full recovery after acute hemorrhagic leukoencephalitis (Hurst's disease)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tumefactive demyelination: an approach to diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The MRI appearance of tumefactive demyelinating lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Primary central nervous system lymphoma: from clinical presentation to diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tumefactive multiple sclerosis requiring emergency craniotomy: case report and literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Rituximab for tumefactive inflammatory demyelination: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tumefactive MS lesions under fingolimod: a case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Baló's concentric sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Astrocytopathy in Balo's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Anti-aquaporin-4 antibody-seronegative NMO spectrum disorder with Baló's concentric lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

The origins of concentric demyelination: self-organization in the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Spinal cord involvement in Balo's concentric sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Baló's concentric sclerosis and tumefactive demyelination: a shared immunopathogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Acute demyelinating disease. Classification and non-invasive diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

An autopsy case of Schilder's variant of multiple sclerosis (Schilder's disease).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

An autopsy case of the Marburg variant of multiple sclerosis (acute multiple sclerosis).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Immune-mediated CNS diseases: a review on nosological classification and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Malignant monophasic multiple sclerosis or "Marburg's disease"

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930043-6

7 January 2021

10.1016/S1474-4422(16)30043-6

Identifiers

DOI

1 reference

29 June 2017

1 reference